Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Mikrobiyol Bul ; 56(3): 387-403, 2022 Jul.
Article in Turkish | MEDLINE | ID: mdl-35960233

ABSTRACT

The Coronavirus disease 2019 (COVID-19) pandemic still continues around the world by making peaks with different variants. In the fight against COVID-19, vaccination is currently the only protective measure. In Turkey, vaccination started firstly in healthcare workers on 13 January 2021 with the CoronaVac (Sinovac Biotech, Chinese) vaccine, and booster doses were administered with the CoronaVac and Comirnaty vaccines in July 2021. In this cross-sectional study, it was aimed to determine the humoral and cellular immunity levels of the employees of the TOBB ETU Hospital 2.5-3.5 months after three doses of vaccination and identify the effective factors. With the power analysis that was conducted with the G*Power software, it was determined to be suitable to include 40 TOBB ETU Hospital workers who had their third dose with the CoronaVac vaccine and 60 workers of the same hospital who had their third dose with the Comirnaty (Pfizer Biontech, Germany) vaccine, and age- and sex-matching was considered by selecting 60 workers randomly from among 223 workers who had Comirnaty as their third dose. The study excluded individuals who had a previous COVID-19 infection or had a positive PCR test result. After collecting blood samples on 18-22 October 2021, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin G levels were studied with the chemiluminescence immunoassay method using a Beckman-Access device (Beckman Coulter Inc., CA, USA) for humoral immunity, and T-SPOT test (T-SPOT. COVID SARS-CoV-2 test-Oxford Immunotec, Singapur) was carried out for cellular immunity. Additionally, demographic data, habits, personal information such as weight and height, reasons for choosing the vaccine and post-vaccine side effects were obtained through the data collection form. Data collection was completed on 29 November 2021. As a result, among the healthcare workers who had received their third dose of vaccine with Comirnaty and CoronaVac; while 25% of those who received three doses of CoronaVac had humoral immunity, 93.3% humoral immunity was determined in the heterogeneous vaccine group with two doses of CoronaVac and one dose of Comirnaty vaccine (p<0.05). Cellular immunity was found to be higher (88.3%, 70%) in those who received the heterologous vaccine than those who completed three doses of the same vaccine (p<0.05). In the heterogeneous vaccination group consisting of the healthcare workers who had their third vaccine dose with Comirnaty and those who had it with CoronaVac, humoral and cellular immunity levels were found high. Among the participants whose humoral immunity was found negative, cellular immunity was present in 75% of those who had Comirnaty as their third dose and 63.3% of those who had CoronaVac. While no significant relationship was found between immunity levels and age, sex or body mass index (BMI), the levels of both forms of immunity were lower in those who had chronic diseases. Among the participants, physicians preferred the third dose of Comirnaty vaccine at a rate of 71.4% and laboratory workers preferred this vaccine at a rate of 80% according to the workplace. In the third dose vaccine preference reasons, it was stated that 55% would continue with the same vaccine, experience fewer side effects, 44% provide more immunity and 9% do not prevent going abroad. The incidence of side effects after the third dose of vaccine was 53% higher in those who received the Comirnaty vaccine than in those who received CoronaVac (35%). Based on these data, it was concluded that heterologous vaccination should be preferred in vaccination strategies, and knowing cellular immunity levels is important for the decision. There is a need for more comprehensive and follow-up studies on how long humoral and especially cellular immunity lasts.


Subject(s)
COVID-19 Vaccines , COVID-19 , Personnel, Hospital , Adult , Antibodies, Viral , COVID-19/immunology , COVID-19/prevention & control , COVID-19 Vaccines/administration & dosage , Cross-Sectional Studies , Female , Humans , Immunity, Cellular , Male , SARS-CoV-2 , Vaccination
2.
Clin Neurol Neurosurg ; 217: 107263, 2022 06.
Article in English | MEDLINE | ID: mdl-35525105

ABSTRACT

BACKGROUND: Retinal abnormalities are being increasingly reported in COVID-19, in addition to the well-known symptoms of this disease accounting for the neurological involvement. In this study, we aimed to investigate whether ganglion cell layer thickness (GCLT) was different in recovered COVID-19 patients compared to controls in the subacute stage and to determine whether it correlated with COVID-19-related neurological symptoms or pneumonia. METHODS: This study involved 40 patients who had recovered from COVID-19 and 40 age- and sex-matched healthy controls. All the participants underwent ophthalmological examination, spectral domain optical coherence tomography and neurological examination. The clinical and biochemical properties of the patients were noted and their correlations with GCLT were sought. RESULTS: The duration after COVID-19 infection was 113 ± 62 (mean ± SD) days. At this subacute stage, there was no significant difference between the GCLT measurements of the COVID-19 patients and the controls (14 ± 4.0 µm [median ± IQR] vs 16 ± 4.8 µm, respectively). When we analyzed the relationships with neurological symptoms in the patient group, we found that patients with cognitive symptoms had lower GCLT values compared to those without (13 ± 3 µm vs. 16 ± 4 µm, respectively; p = 0.002). Patients who suffered headache during the acute infection also had lower GCLT values compared to those without (14 ± 4 µm vs. 18 ± 5 µm, respectively; p = 0.015). The GCLT values did not differ significantly with respect to anosmia, ageusia, sleep disturbances, having had COVID-19 pneumonia, or smoking status. Age, duration after COVID-19, and blood levels of thyroid stimulating hormone, glucose, vitamin D and vitamin B12 were not in correlation with GCLT in our study. CONCLUSION: Our findings highlight an association between GCLT values and neurological symptoms such as cognitive disturbance (brain fog) and headache in patients who had recovered after non-severe COVID-19 infection. Neuroretinal involvement by SARS-CoV2 might be linked to central neurological symptoms. The patients with lower GCLT values may benefit from close monitoring for neurological problems.


Subject(s)
COVID-19 , COVID-19/complications , Cognition , Headache/etiology , Humans , RNA, Viral , SARS-CoV-2 , Tomography, Optical Coherence
3.
Tuberk Toraks ; 70(1): 27-36, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35362302

ABSTRACT

Introduction: Neurological aspect of COVID-19 is less understood compared to its respiratory and systemic effects. We aimed to define subacute neurological sequelae in patients who recovered from mild COVID-19. Materials and Methods: This study enrolled long COVID patients who had mild infection, were non-hospitalized, and admitted to our hospital with neurological complaints occurring after COVID-19. The evaluation included detailed history of the symptoms, neurological examination, blood tests and necessary investigations relevant to their personal medical situation, and also a retrospective inquiry about their respiratory and neurological status during the acute phase of infection. Descriptive statistical measures, Chi-square and Student's t-test were utilized. Result: We identified 50 patients (29F/21M) with a mean age of 36.9 ± 1.6 (mean ± SEM). The average time from COVID-19 to admission was 99 days(min-max= 15-247). Most frequent neurological complaints were headache (42%) and cognitive dysfunction (42%). Sleep disturbance (36%), prolonged anosmia (30%), prolonged ageusia (22%), fatigue (22%), and dizziness (8%) followed. Most patients with headache experienced headache also as an acute manifestation of COVID-19 (p= 0.02). Acute-stage sleep disorders were found to be more associated with subacute cognitive symptoms than other central symptoms (p= 0.008). The most common neurological symptom in the acute phase was headache (74%). Six patients, despite the absence of any acute-stage neurological symptoms, presented with emergence of subacute neurological sequela. There were only five patients with pulmonary involvement during the acute stage, who were not different from the rest of the cohort in terms of neurological sequelae. There was no increase of inflammatory markers in the blood tests at the subacute stage, or no association of the symptoms to biochemical parameters. Conclusions: This study gives a description of neurological sequelae of mild COVID-19 at the subacute stage, in a relatively young group, and reveals that cognitive disturbances, as well as headache, are quite frequent.


Subject(s)
COVID-19 , Adult , COVID-19/complications , Headache/complications , Headache/etiology , Humans , Outpatients , Retrospective Studies , Post-Acute COVID-19 Syndrome
4.
Environ Toxicol Pharmacol ; 86: 103657, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33838330

ABSTRACT

Diesel exhaust particles (DEP) are the major components of atmospheric particulate matter (PM) and chronic exposure is recognized to enhance respiratory system complications. Although the spread of SARS-CoV-2 was found to be associated with the PMs, the mechanism by which exposure to DEP increases the risk of SARS-CoV-2 infection is still under discussion. However, diesel fine PM (dPM) elevate the probability of SARS-CoV-2 infection, as it coincides with the increase in the number of ACE2 receptors. Expression of ACE2 and its colocalized activator, transmembrane protease serine 2 (TMPRSS2) facilitate the entry of SARS-CoV-2 into the alveolar epithelial cells exposed to dPM. Thus, the coexistence of PM and SARS-CoV-2 in the environment augments inflammation and exacerbates lung damage. Increased TGF-ß1 expression due to DEP accompanies the proliferation of the extracellular matrix. In this case, "multifocal ground-glass opacity" (GGO) in a CT scan is an indication of a cytokine storm and severe pneumonia in COVID-19.


Subject(s)
Air Pollution/adverse effects , COVID-19/diagnostic imaging , COVID-19/epidemiology , Lung/diagnostic imaging , Vehicle Emissions/toxicity , Angiotensin-Converting Enzyme 2/biosynthesis , Angiotensin-Converting Enzyme 2/genetics , Humans , Particulate Matter , Tomography, X-Ray Computed
5.
Tuberk Toraks ; 66(1): 68-71, 2018 Mar.
Article in English | MEDLINE | ID: mdl-30020045

ABSTRACT

Foreign body aspiration is a serious health problem in all age groups, and in pregnancy it may cause serious complications for the fetus as well as the pregnant woman. Here we present our case of a 36 years old 22 weeks pregnant woman, accidentally aspirating roasted chickpea upon laughing. She had the complaints of coughing and shortness of breath on admission, bronchoscopy was performed, and the roasted chickpea blocking the entrance of right lower lobe bronchus was removed without any complications. For foreign body aspiration in pregnancy, bronchoscopy is a rather safer procedure when performed by an experienced team.


Subject(s)
Cicer , Foreign Bodies/therapy , Pregnant Women , Respiratory Aspiration/therapy , Bronchoscopy/methods , Female , Foreign Bodies/diagnostic imaging , Humans , Pregnancy , Respiratory Aspiration/diagnostic imaging , Trachea/diagnostic imaging
6.
Mol Imaging Radionucl Ther ; 23(3): 89-95, 2014 Oct 05.
Article in English | MEDLINE | ID: mdl-25541932

ABSTRACT

OBJECTIVE: The aim of this study was to investigate the relationship between patient characteristics and adenosine-related side-effects during stress myocard perfusion imaging (MPI). The effect of presence of adenosine-related side-effects on the diagnostic value of MPI with integrated SPECT/CT system for coronary artery disease (CAD), was also assessed in this study. METHODS: Total of 281 patients (109 M, 172 F; mean age:62.6±10) who underwent standard adenosine stress protocol for MPI, were included in this study. All symptoms during adenosine infusion were scored according to the severity and duration. For the estimation of diagnostic value of adenosine MPI with integrated SPECT/CT system, coronary angiography (CAG) or clinical follow-up were used as gold standard. RESULTS: Total of 173 patients (61.6%) experienced adenosine-related side-effects (group 1); flushing, dyspnea, and chest pain were the most common. Other 108 patients completed pharmacologic stress (PS) test without any side-effects (group 2). Test tolerability were similar in the patients with cardiovascular or airway disease to others, however dyspnea were observed significantly more common in patients with mild airway disease. Body mass index (BMI) ≥30 kg/m2 and age ≤45 years were independent predictors of side-effects. The diagnostic value of MPI was similar in both groups. Sensitivity of adenosine MPI SPECT/CT was calculated to be 86%, specificity was 94% and diagnostic accuracy was 92% for diagnosis of CAD. CONCLUSION: Adenosine MPI is a feasible and well tolerated method in patients who are not suitable for exercise stress test as well as patients with cardiopulmonary disease. However age ≤45 years and BMI ≥30 kg/m2 are the positive predictors of adenosine-related side-effects, the diagnostic value of adenosine MPI SPECT/CT is not affected by the presence of adenosine related side-effects.

7.
Int J Clin Exp Med ; 7(1): 170-6, 2014.
Article in English | MEDLINE | ID: mdl-24482704

ABSTRACT

OBJECTIVE: To evaluate the patients' attitudes about the devices, of which they use for long-term respiratory support at home. METHOD: 200 consecutive patients were questioned about the treatment and devices of respiratory support at home by face to face questionnaire. Their records were taken from the archives of Social Security Agency. RESULTS: 123 (61.5%) of the patients were men and 77 (38.5%) were women. The mean age was 65.8 ± 11.9 (15-92) years. The most frequently prescribed device was oxygen concentrator and BIPAP was the one that follows. The most common indications were hypoxic and hypercapnic respiratory failure due to COPD. The devices were prescribed by the state university hospitals, most commonly. The average daily oxygen usage duration was 16.3 ± 3.1 hours, the average duration was 7.4 ± 3.1 hours, for BIPAP. Twenty one (11.4%) of the patients, who were treated with LTOT, stated that they were taking oxygen less than 15 hours a day. Higher education levels of the patients was correlated with the higher rates of visiting the companies - that they bought the devices- both for information about and control of the devices (p=0.002). The rate of visiting companies/firms was significantly higher in patients, who use BIPAP and respiratory support combined with it (p=0.010). Twenty three (47.9%) of the 48 patients, who notified that their devices were impaired, waited for repairment by the firm, 20 (41.6%) investigated special repair facilities and the rest (10.5%) rented a new device. CONCLUSION: Effective and continuous technical maintenance support must be provided to the patients, who are treated with long-term respiratory support at home.

8.
Tuberk Toraks ; 56(4): 390-5, 2008.
Article in English | MEDLINE | ID: mdl-19123074

ABSTRACT

Epidermal growth factor receptor (EGFR) has been implicated as a factor indicating tumour progression or as a prognostic factor in non-small cell lung cancer (NSCLC), in which its overexpression is often detected. The usefulness of identifying EGFR in serum from patients with NSCLC is controversial. This study was designed to identify serum EGFR levels in patients with NSCLC and to evaluate the relationship between serum EGFR levels and clinical stage, histological subtype and survival time. Serum EGFR levels were measured using quantitative enzyme-linked immunosorbent assay. The study included 43 patients with NSCLC and 16 healthy controls. The histological classification was 29 squamous carcinomas and 14 adenocarcinomas. Serum samples were collected before treatment.There was no difference between serum EGFR levels in patients with NSCLC (17.53+/-8.09 fmol/mL) in comparison with those healthy controls (16.88+/-7.08 fmol/mL; p=0.912). There was also no difference in serum EGFR levels according to clinical stage or histological subtype. There was no relationship between serum EGFR levels and survival time in patients with NSCLC. The study's results suggest that, the utility of serum EGFR levels in patients with NSCLC as a tumour marker or as a prognostic factor is limited. However, further prospective studies on a large number of patients will be necessary to confirm this study's results.


Subject(s)
Carcinoma, Non-Small-Cell Lung/blood , ErbB Receptors/blood , Gene Expression Regulation, Neoplastic , Lung Neoplasms/blood , Adenocarcinoma/pathology , Adult , Aged , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Case-Control Studies , Disease Progression , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Prognosis , Survival Rate
9.
Tuberk Toraks ; 54(1): 17-21, 2006.
Article in English | MEDLINE | ID: mdl-16615013

ABSTRACT

Interferon (IFN)-gamma plays a pivotal role in protective immunity against Mycobacterium tuberculosis. Elevations of IFN-gamma have been found in the affected lung and bloodstream of patients with pulmonary tuberculosis. In the present study, we aimed to investigate the role of serum IFN-gamma level in the differential diagnosis of active and inactive pulmonary tuberculosis. Fourty seven patients with newly diagnosed active pulmonary tuberculosis, 21 patients with inactive pulmonary tuberculosis, and 20 healthy volunteers were enrolled in the study. Serum samples were collected from each subject and stored at - 70 degrees C until the analysis of IFN-gamma. The mean value of IFN-gamma levels were 9.3 +/- 4.6 pg/mL in patients with newly diagnosed pulmonary tuberculosis, 9.8 +/- 3.8 pg/mL in patients with inactive tuberculosis, and 10.2 +/- 3.4 pg/mL in healthy controls. The comparison of IFN-gamma levels of the three groups was not found statistically significant (p= 0.4). Serum IFN-gamma level was not found to be valuable in the differential diagnosis of active and inactive pulmonary tuberculosis.


Subject(s)
Interferon-gamma/blood , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Severity of Illness Index , Tuberculosis, Pulmonary/blood , Tuberculosis, Pulmonary/pathology
10.
Tuberk Toraks ; 52(4): 373-7, 2004.
Article in English | MEDLINE | ID: mdl-15558361

ABSTRACT

Metastatic non-small cell lung cancer (NSCLC) has a poor prognosis. Adrenal metastasis (AM), in NSCLC, are present in 5-10% of patients at initial presentation. Several case reports have shown that operation of isolated AM results in longer survival time. We describe a 55 year-old man with diagnosis of NSCLC with operable lung tumor and solitary AM treated with combination of neoadjuvant chemotherapy followed by primary site and metastasis surgery. He was diagnosed on March 2002 and is still alive.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Carcinoma, Non-Small-Cell Lung/diagnosis , Lung Neoplasms/diagnosis , Adrenal Gland Neoplasms/diagnostic imaging , Adrenal Gland Neoplasms/secondary , Adrenal Gland Neoplasms/therapy , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/secondary , Carcinoma, Non-Small-Cell Lung/therapy , Combined Modality Therapy , Diagnosis, Differential , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Male , Middle Aged , Neoadjuvant Therapy , Tomography, X-Ray Computed
11.
Tuberk Toraks ; 52(3): 211-7, 2004.
Article in English | MEDLINE | ID: mdl-15351932

ABSTRACT

We studied ADA and gamma interferon (gamma-IFN) levels in pleural fluid of 45 cases presenting with pleural effusion to the Ankara University School of Medicine Chest Diseases Hospital between September 2001 and September 2002. Fifteen patients had TB pleurisy, 20 patients had malignant pleurisy and 10 patients had transudative pleural effusion. The cut-off value for pleural fluid gamma-IFN levels were 12 pg/mL. According to this, all patients with transudative effusions, 19 of 10 patients with malignant effusions and 2 of 15 patients with tuberculous (TB) effusions had pleural fluid gamma-IFN levels under the cut-off value. In exudative effusions, sensitivity and specificity of gamma-IFN were 87% and 95% respectively. The sensitivity of pleural fluid ADA levels was 86% and specificity of pleural fluid ADA levels was 100%. Pleural fluid ADA levels in TB effusions were significantly higher than the non-TB effusions. Also there were no statistically significant differences between pleural fluid ADA and g-IFN levels according to sensitivity and specificity. As a result, we have shown that gamma-IFN is a valuable test in diagnosis of TB pleurisy. We think that when it is used routinely, it will be a good alternative to the conventional invasive diagnostic tests.


Subject(s)
Interferon-gamma/metabolism , Pleurisy/diagnosis , Tuberculosis, Pleural/diagnosis , Adenosine Deaminase/metabolism , Adolescent , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Case-Control Studies , Female , Humans , Male , Middle Aged , Pleural Effusion/metabolism , Pleurisy/metabolism , Predictive Value of Tests , Receptors, Interleukin-2/metabolism , Sensitivity and Specificity , Tuberculosis, Pleural/metabolism
12.
Respir Med ; 98(7): 632-6, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15250229

ABSTRACT

BACKGROUND: Angiogenesis, the formation of new blood vessels from the existing vascular bed, is essential step for the growth and invasion of the primary tumor. Vascular endothelial growth factor (VEGF) is known to play crucial role in tumor angiogenesis. Increased serum VEGF levels may be associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). METHODOLOGY: In the present study, we measured plasma VEGF levels in 20 normal subjects and 75 patients with untreated NSCLC; 23 operable (stages I, II, IIIA) and 52 inoperable (stages IIIB, IV) (Histology: squamous cell carcinoma, 40; adenocarcinoma, 27; undetermined, 8). VEGF was measured by enzyme-linked immunosorbent assay. RESULTS: The median VEGF level in patient group was 119 pg/ml (29-1235), which was significantly higher than the control group (P = 0.044). Median survival of patients was 210 days (30-220). The patients were divided into high VEGF (> 119 pg/ml) and low VEGF (< 119 pg/ml) groups using the median value as a cut-off. It was investigated if there were significant associations between serum VEGF level and clinico-pathological parameters like age, sex, histopathological diagnosis and TNM staging. Also high VEGF and low VEGF patient groups were compared according to the median survival. CONCLUSIONS: Serum VEGF level is significantly associated with the clinical staging of the patients (operable and inoperable) (P = 0.031) and it also correlates with the prognosis of the patients (P = 0.0006).


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Non-Small-Cell Lung/blood , Lung Neoplasms/blood , Vascular Endothelial Growth Factors/blood , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/pathology , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Proteins/blood , Neoplasm Staging , Prognosis , Statistics, Nonparametric , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...